# US 2016/0250338 A1 · Micellic assemblies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250338 A1
- Document ID: US20160250338A1
- Status: Published application
- Kind: A1
- Application number: 15/059,026
- Filed: 2016-03-02
- Published: 2016-09-01
- Earliest claimed: 2008-05-13
- Assignees: University of Washington; PhaseRx, Inc.
- Applicants: University of Washington; PhaseRx, Inc.
- Inventors: Patrick S. Stayton; Allan S. Hoffman; Anthony Convertine; Craig L. Duvall; Danielle Benoit; Robert Overell; Paul H. Johnson; Anna S. Gall; Mary G. Prieve; Amber E.E. Paschal; Charbel Diab; Priyadarsi De
- Web page: https://patentgrep.com/patent/US20160250338A1

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/58: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6907: {the form being a microemulsion, nanoemulsion or micelle}
- A61K 48/0041: {the non-active part being polymeric}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C08F 290/062: {Polyethers}
- C08F 293/005: {using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.

## Claims

### Claim 1

A micelle comprising a core and a shell, the micelle comprising a plurality of block copolymers of Formula I:
wherein
A0, A1, Az, A3, and A4 are independently selected from the group consisting of —C—C—, —C(O)(C)aC(O)O—, and —O(C)aC(O)—, wherein a is 1-4;
Y4 is selected from the group consisting of hydrogen, -(1C-10C)alkyl, -(3C-6C)cycloalkyl, —O-(1C-10C)alkyl, —C(O)O(1C-10C)alkyl, -(4C-10C)heteroaryl, and -(6C-10C)aryl, any of which is optionally substituted with one or more fluorine groups;
Y0, Y1, and Y2 are independently selected from the group consisting of a covalent bond, -(1C-10C)alkyl-, —C(O)O(2C-10C)alkyl-, —OC(O)(1C-10C)alkyl-, —O(2C-10C)alkyl-, —S(2C-10C)alkyl-, —C(O)NR6(2C-10C)alkyl-, -(4C-10C)heteroaryl, and -(6C-10C)aryl;
Y3 is selected from the group consisting of a covalent bond, -(1C-10C)alkyl-, -(4C-10C)heteroaryl, and -(6C-10C)aryl-; wherein tetravalent carbon atoms of A0-A4 that are not fully substituted with R1-R5 and Y0-Y4 are completed with an appropriate number of hydrogen atoms;
R1, R2, R3, R4, R5, and R6 are independently selected from the group consisting of hydrogen, —CN, alkyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which may be optionally substituted with one or more fluorine atoms;
Q0 is a residue selected from the group consisting of residues which are hydrophilic at physiologic pH; conjugatable or functionalizable residues; and hydrogen;
Q1 is a residue which is hydrophilic at normal physiological pH;
Q2 is a residue which is positively charged at normal physiological pH;
Q3 is a residue which is negatively charged at normal physiological pH, but undergoes protonation at lower pH;
m is a mole fraction of 0 to less than 1.0;
n is a mole fraction of greater than 0 to 1.0; wherein m+n=1;
p is a mole fraction of 0.1 to 0.9;
q is a mole fraction of 0.1 to 0.9;
r is present up to a mole fraction of 0.8; wherein p+q+r=1;
v is from 1 to 25 kDa; and
w is from 1 to 50 kDa.

### Claim 2 (depends on 1)

The micelle of claim 1, wherein each of A0, A1, A2, A3, and A4 is —C—C—.

### Claim 3 (depends on 1)

The micelle of claim 1, wherein m is a mole fraction of 0 to 0.49.

### Claim 4 (depends on 2)

The micelle of claim 2, wherein m is a mole fraction of 0 to 0.49.

### Claim 5 (depends on 1)

The micelle of claim 1, wherein p is a mole fraction of 0.2 to 0.5.

### Claim 6 (depends on 2)

The micelle of claim 2, wherein p is a mole fraction of 0.2 to 0.5.

### Claim 7 (depends on 1)

The micelle of claim 1, wherein p and q are within 0.3 of each other.

### Claim 8 (depends on 2)

The micelle of claim 2, wherein p and q are within 0.3 of each other.

### Claim 9 (depends on 1)

The micelle of claim 1, wherein w is from 5 to 50 kDa.

### Claim 10 (depends on 2)

The micelle of claim 2, wherein w is from 5 to 50 kDa.

### Claim 11 (depends on 1)

The micelle of claim 1, wherein the ratio of w to v is from 5:1 to 1:1.

### Claim 12 (depends on 2)

The micelle of claim 2, wherein the ratio of w to v is from 5:1 to 1:1.

### Claim 13 (depends on 1)

The micelle of claim 1, wherein Q0 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, thiol, azide, alkyne, succinimide ester, tetrafluorophenyl ester, pentafluorophenyl ester, p-nitrophenyl ester, pyridyl disulfide, and hydrogen;
Q1 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, and thiol;
Q2 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, and pyridyl; and
Q3 is a residue selected from the group consisting of carboxyl, boronate, phosphonate, and phosphate.

### Claim 14 (depends on 2)

The micelle of claim 2, wherein Q0 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, thiol, azide, alkyne, succinimide ester, tetrafluorophenyl ester, pentafluorophenyl ester, p-nitrophenyl ester, pyridyl disulfide, and hydrogen;
Q1 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, and thiol;
Q2 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, and pyridyl; and
Q3 is a residue selected from the group consisting of carboxyl, boronate, phosphonate, and phosphate.

### Claim 15 (depends on 1)

The micelle of claim 1, wherein the micelle comprises a targeting moiety.

### Claim 16 (depends on 15)

The micelle of claim 15, wherein the targeting moiety binds to the asialoglycoprotein receptor.

### Claim 17 (depends on 2)

The micelle of claim 2, wherein the micelle comprises a targeting moiety.

### Claim 18 (depends on 17)

The micelle of claim 17, wherein the targeting moiety binds to the asialoglycoprotein receptor.

### Claim 19 (depends on 1)

The micelle of claim 1, wherein the micelle has an average hydrodynamic diameter of 10 nm to 100 nm.

### Claim 20 (depends on 2)

The micelle of claim 2, wherein the micelle has an average hydrodynamic diameter of 10 nm to 100 nm.
